- Home
- OPT vs MBUU Comparison
OPT vs MBUU Comparison
Compare OPT & MBUU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- MBUU
- Stock Information
- Founded
- OPT 1984
- MBUU 1982
- Country
- OPT Australia
- MBUU United States
- Employees
- OPT N/A
- MBUU 2250
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- MBUU Marine Transportation
- Sector
- OPT Health Care
- MBUU Industrials
- Exchange
- OPT Nasdaq
- MBUU Nasdaq
- Market Cap
- OPT 574.0M
- MBUU 699.9M
- IPO Year
- OPT 2020
- MBUU 2014
- Fundamental
- Price
- OPT $3.90
- MBUU $35.50
- Analyst Decision
- OPT Strong Buy
- MBUU Buy
- Analyst Count
- OPT 1
- MBUU 7
- Target Price
- OPT $12.00
- MBUU $42.17
- AVG Volume (30 Days)
- OPT 18.3K
- MBUU 149.4K
- Earning Date
- OPT 02-26-2025
- MBUU 01-28-2025
- Dividend Yield
- OPT N/A
- MBUU N/A
- EPS Growth
- OPT N/A
- MBUU N/A
- EPS
- OPT N/A
- MBUU N/A
- Revenue
- OPT $261,859.00
- MBUU $744,785,000.00
- Revenue This Year
- OPT N/A
- MBUU $4.07
- Revenue Next Year
- OPT $46,864.26
- MBUU $10.12
- P/E Ratio
- OPT N/A
- MBUU N/A
- Revenue Growth
- OPT N/A
- MBUU N/A
- 52 Week Low
- OPT $1.79
- MBUU $30.20
- 52 Week High
- OPT $5.45
- MBUU $54.31
- Technical
- Relative Strength Index (RSI)
- OPT 56.41
- MBUU 38.50
- Support Level
- OPT $3.59
- MBUU $34.61
- Resistance Level
- OPT $3.90
- MBUU $38.00
- Average True Range (ATR)
- OPT 0.24
- MBUU 1.10
- MACD
- OPT 0.02
- MBUU 0.08
- Stochastic Oscillator
- OPT 74.11
- MBUU 39.27
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About MBUU Malibu Boats Inc.
Malibu Boats is a leading designer and manufacturer of power boats in the United States. It is the market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a leading producer of sterndrive boats in the us in the 24- to 29-foot segment, in 2017 and Pursuit Boats, which makes high-end offshore and outboard motorboats, in 2018. In 2021, it purchased Maverick Boat Group, a leading seller of flat fishing boats, including bay, dual-console, and center-console boats. Malibu has also expanded into boat trailers and accessories and in 2020 began producing its own engines (Monsoon) for its performance sport boats and now for Cobalt. Malibu's target market includes a wide range of water enthusiasts who embrace the active outdoor lifestyle.